贝伐珠单抗联合顺铂腹腔给药治疗胃癌腹水的效果

Effect of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites

目的观察贝伐珠单抗联合顺铂腹腔给药治疗胃癌腹水的效果。方法选取2017年6月至2020年6月于中国人民解放军联勤保障部队第九〇四医院就诊的胃癌腹水患者102例。采用随机数字法将其分为对照组和研究组,每组各51例。对照组给予顺铂腹腔给药治疗,研究组在对照组的基础上联合贝伐珠单抗治疗,以21 d为1个治疗周期,共治疗2个周期。比较两组疗效及治疗前后腹水中肿瘤标志物水平[糖类抗原(CA)125、癌胚抗原(CEA)、CA199]及基质金属蛋白酶(MMP)-2、Gil1、MMP-9的mRNA表达。记录两组不良反应发生情况。结果研究组的客观缓解率、疾病控制率均高于对照组,差异有统计学意义(P<0.05)。两组治疗2个周期后腹水中CEA、CA125、CA199水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组治疗2个周期后腹水MMP-2、Gil1、MMP-9 mRNA表达均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论贝伐珠单抗联合顺铂腹腔给药治疗胃癌腹水,可有效缓解其进展,效果可靠。

Objective To observe the efficacy of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites.Methods A total of 102 patients with gastric cancer and ascites admitted to the No.904 Hospital of PLA Joint Service Support Force from June 2017 to June 2020 were selected.The patients were divided into control group and study group by random number method,with 51 cases in each group.The control group was given Cisplatin intraperitoneal administration,and the research group was combined with Bevacizumab on the basis of the control group,with 21 days as a treatment cycle,a total of two cycles of treatment.The efficacy of the two groups was compared.The levels of tumor markers(carbohydrate antigen[CA]125,carcinoembryonic antigen[CEA],CA199),and mRNA expression of matrix metalloproteinase(MMP)-2,Gil1,and MMP-9 in ascites were compared between the two groups.The incidence of adverse reactions in the two groups was recorded.Results The objective remission rate and disease control rate in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After two cycles of treatment,the levels of CEA,CA125,and CA199 in ascites in both groups were lower than before treatment,and those in the study group were lower than those in the control group,with statistical significance(P<0.05).After two cycles of treatment,the mRNA expressions of MMP-2,Gil1,and MMP-9 in ascites in both groups were lower than before treatment,and those in the study group were lower than those in the control group,with statistical significance(P<0.05).There was no significant difference in the total incidence of adverse reaction between the two groups(P>0.05).Conclusion Intraperitoneal administration of Bevacizumab combined with Cisplatin in the treatment of ascites in gastric cancer can effectively alleviate the progression of ascites with reliable efficacy.